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Abstract
Background: Lung cancer is the leading cause of death from cancer worldwide. Conventional
studies mainly think that insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3)
may promote and inhibit tumor growth, respectively. However, there are many different results
about their function in some recent epidemiological studies. To evaluate the relationship between
circulating serum levels of IGF-I, IGFBP-3 and lung cancer, a systematic review and meta-analysis of
the published data was performed.
Methods: Literatures searched on PubMed and Embase databases were enrolled in the Meta-
analysis. The Meta-analysis of all eligible studies was applied with Stata 10.0 software, and the
pooled odds ratio(OR) and weighted mean difference (WMD) value were obtained. The Q test,
Egger's test and Begg's funnel plot were used to evaluate the heterogeneity and publication bias
between the studies.
Results: There are no statistically significant heterogeneity and publication bias between the
studies. For IGF- I, the pooled OR and WMD were 0.87(95%CI: 0.60~1.13,) and -3.04(95%CI: -
7.10~1.02, P = 0.14), respectively. For IGFBP-3, the pooled OR and WMD were 0.68(95%CI:
0.48~0.88,) and -112.28(95%CI: -165.88~-58.68, P < 0.0001), respectively.
Conclusion: The association between circulating IGF- I levels and the risk of lung cancer were not
statistically significant; IGFBP-3, acts as a tumor suppressor and has a inverse correlation with the
risk of lung cancer.
Background
Lung cancer is the leading cause of death from cancer
worldwide, and the care rate remains less than 15%
despite improvements in surgery, radiotherapy and chem-
otherapy [1]. Insulin-like growth factor-I (IGF-I) and IGF-
binding protein-3 (IGFBP-3) have been widely accepted
that they may have key role on the genesis and develop-
ment of many types of tumor including lung cancer [2-7].
Growth hormone stimulates production of IGF-I in the
liver and peripheral tissues. IGF-I is also released locally in
response to damage, either directly or through the action
of other factors associated with tissue responses to dam-
age, including epidermal growth factor, fibroblast growth
factor, and platelet-derived growth factor [8]. IGFBP-3 is
the dominant circulating binding partner for both IGFs,
accounting for 70 to 80% of their blood levels [8,9]. Mul-
Published: 24 June 2009
Journal of Experimental & Clinical Cancer Research 2009, 28:89 doi:10.1186/1756-9966-28-89
Received: 14 May 2009
Accepted: 24 June 2009
This article is available from: http://www.jeccr.com/content/28/1/89
© 2009 Chen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89
Page 2 of 6
(page number not for citation purposes)
tiple lines of evidence suggest involvement of the IGF
pathway across a range of malignancies, including both
non-small cell lung cancer (NSCLC) and small cell lung
cancer [5,10,11]. Elevated plasma levels of IGF-I have
been associated with an increased risk of lung cancer, and
high plasma levels of IGFBP-3 associated with a reduced
risk [5]. Similarly, IGFBP-3 promoter methylation in
tumor cells has been linked to decreased survival in stage
I NSCLC patients. These suggest that IGF-I may promote
tumor cell growth, while IGFBP-3 acts as a tumor suppres-
sor gene [12,13]. At the same time, different results were
obtained from other studies. Recently, many large-scale
clinical prospective case-control studies on association
between circulating levels of IGF-I, IGFBP-3 and the risk of
lung cancer were performed [14-19]. However, the results
of these studies still remain inconclusive, partially because
of the possible relatively small sample size in each of the
published studies.
Here we performed a systematic meta-analysis of all stud-
ies published to date to determine and assess the strength
of the association between circulating levels of IGF- I and
IGFBP-3 and lung cancer. It may be helpful in the diagno-
sis and treatment of lung cancer.
Methods
Search strategy and study selection
PubMed and Embase were searched using the search
terms: "insulin-like growth factor-I", "lung neoplasm",
"case-control study", "cohort study" and "prospective
study" (last search was updated on 1 March 2009). All eli-
gible studies were retrieved, and their bibliographies were
checked for other relevant publications. Review articles
and bibliographies of other relevant studies identified
were hand-searched to find additional eligible studies.
These searches were restricted to studies in which IGF-I
and IGFBP-3 concentration were measured. Two investi-
gators independently reviewed all potentially relevant
articles. Disagreement or uncertainty between 2 investiga-
tors was resolved by discussion. Inclusion was restricted to
nested case-control studies and prospective cohort stud-
ies published in English.
Data extraction
Data were independently abstracted in duplicate by 2
investigators using a standard protocol and data-collec-
tion form. Characteristics abstracted from the studies
included name of the first author, location of the study,
year of publication, case definition, control definition,
selection criteria, method of IGF-I and IGFBP-3 measure-
ment, confounding factors that were controlled for by
matching or adjustment and mean and standard devia-
tion (SD) of IGF-I and IGFBP-3 in each group, odds ratio
(OR) comparing the highest category to the lowest and its
95% confidence interval(CI). For data not provided in
tabular form or the main text, the required information
were obtained by contacting corresponding authors as
possible as we can.
Statistical analysis
Most of studies provided crude and adjusted OR. We used
the adjusted OR comparing the highest category with the
Table 1: Characteristics of case-control studies for lung cancer and IGF-I and IGFBP-3
Study Year, location Sample size
(case/control)
Measurement OR(95%CI) for IGF-I OR(95%CI) for IGFBP-3 Adjusted factors in the 
model in original report
IGF-1 IGFBP3
Lukanova et al.[14] 2001, USA 93/186 RIA RIA 0.54(0.14–2.07) 0.90(0.28–2.85) Age, date of recruitment 
in the study, menopausal 
status, current smoking, 
time since last meal, 
cotinine and BMI
London et al.[15] 2002, China 230/740 RIA IRMA 0.86(0.47–1.57) 0.50(0.25–1.02) Smoking
Spitz et al.[16] 2002, USA 159/297 ELISA ELISA 0.64(0.31–1.33) 2.35(1.13–4.92) Age, sex, race, year of 
enrollment, and year of 
blood draw, BMI, 
smoking status, pack-
years of smoking, 
exposure population
Waikai et al.[17] 2002, Japan 194/9351 IRMA IRMA 1.74(1.08–2.81) 0.67(0.45–1.01) Age, area, gender, 
smoking habits, and BMI
Ahn et al.[18] 2006, Finland 200/400 ELISA ELISA 0.76(0.39–1.49) 0.71(0.35–1.47) Age, intervention arm, 
BMI, and years of 
smoking
Morris et al. [19] 2006, British 167/498 ELISA ELISA 1.21(0.62–2.35) 1.70(0.87–3.30) Age, smoking
All are nested case-control studies within cohort study.
BMI indicates body mass index.
IRMA, immunoradiometric assay; ELISA, enzyme-linked immunoabsorbent assay; RIA, radioimmunoassay assay.Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89
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lowest as the principal effect measure in our meta-analy-
sis. The cutoff values for these categories were based on
control groups, which better represented the distribution
of IGF-I and IGFBP-3 in the general population. The
adjusted ORs and their 95% confidence intervals were
abstracted directly from the publications. We also used
the weighted mean difference (WMD) to compare circu-
lating levels of IGF-1 and IGFBP-3 of lung cancer cases
with that of their controls.
Heterogeneity assumption was checked by the chi-square-
based Q test [20]. A P value > 0.10 for the Q test indicates
a lack of heterogeneity among studies, so the pooled OR
estimate of the each study was calculated by the fixed-
effects model (the Mantel-Haenszel method) [21]. Other-
wise, the random- effects model (the DerSimonian and
Laird method) was used [22]. An estimate of potential
publication bias was carried out by the funnel plot, in
which the standard error of log (OR) of each study was
plotted against its log (OR). An asymmetric plot suggests
a possible publication bias. Funnel plot asymmetry was
assessed by the method of Egger's linear regression test, a
linear regression approach to measure funnel plot asym-
metry on the natural logarithm scale of the OR. The signif-
icance of the intercept was determined by the t test
suggested by Egger (P < 0.05 was considered representa-
tive of statistically significant publication bias) [23]. Stata
statistical package version 10.0(Stata Corporation, Col-
Funnel plot for publication bias in the analysis of IGF-I and  lung cancer Figure 2
Funnel plot for publication bias in the analysis of IGF-
I and lung cancer. Each circle indicates the logarithm of the 
odds ratio of lung cancer comparing the subjects in the high-
est category with the lowest (vertical axis) and the standard 
error of logarithm of odds ratio in each study. The line in the 
centre indicates the summary diagnostic odds ratio.
Begg's funnel plot with pseudo 95% confidence limits
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Table 2: Studies reporting IGF-I and IGFBP-3 levels in lung cancer patients and their controls
Serum factors References Cases Cases
N1 Mean(ng/ml) SD(ng/ml) N2 Mean(ng/ml) SD(ng/ml)
IGF-1 [14] 93 --- --- 186 --- ---
[15] 230 123 46.43 740 127 41.62
[16] 159 158 56 297 153 54
[17] 194 124 54 9351 126 57
[18] 200 137.2 52.3 400 145.5 52
[19] 167 --- --- 498 --- ---
IGFBP-3 [14] 93 --- --- 186 --- ---
[15] 230 1793 487.43 740 1863 458.76
[16] 159 30700 8200 297 29400 7900
[17] 194 2780 860 9351 2990 810
[18] 200 2228 650 400 2369 640
[19] 167 --- --- 498 --- ---
N1 is the number of cases, N2 is the number of controls; ---, not available.
Graphic representation of the meta-analysis for IGF-I and  lung cancer Figure 1
Graphic representation of the meta-analysis for IGF-I 
and lung cancer. The ORs and their 95% confidence inter-
vals in the original studies are shown..
 OR
 Study  (95% CI)  % Weight
 Lukanova 2001   0.54 ( 0.14, 2.07)   7.6 
 OR
 -3  0  1  3
 London 2002   0.86 ( 0.47, 1.57)    23.3 
 Spitz 2002   0.64 ( 0.31, 1.33)    27.1 
 Waikai 2002   1.74 ( 1.08, 2.81)   9.4 
 Ahn 2006   0.76 ( 0.39, 1.49)    23.3 
 Morris 2006   1.21 ( 0.62, 2.35)   9.4 
 Overall   0.87 ( 0.60, 1.13)      100.0 Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89
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lege Station, TX) was used for the meta-analysis, using
two-sided P-values.
Results
Characteristics of studies included in the meta-analysis
Twenty-two articles were identified by the PubMed and
Embase databases search. After reading abstracts and full
text of them, 6 articles met the inclusion criteria. All of
them are nested case-control within cohort studies as
shown in Table 1. Among the 6 studies, 2 studies were
conducted in the United States and 4 were done in China,
Japan, Finland and British. The number of cases and con-
trols ranged from 93 to 230 and 186 to 9,351, respec-
tively. The total numbers of cases and controls in these
studies were 1,043 and 11,472.
Statistical heterogeneity
After performing the tests for heterogeneity for IGF-I and
IGFBP-3 separately, we decided to use a fixed-effect model
to obtain a summary statistic as the tests were not statisti-
cally significant (Q-value of 5.86 with df = 5, P = 0.320 for
IGF-I and Q-value of 6.66 with df = 5, P = 0.247 for
IGFBP-3).
Meta-analysis results
We abstracted OR comparing the highest category to the
lowest and its 95% CI and mean, SD of IGF-I and IGFBP-3,
separately. And the data are shown in Table 1 and Table 2.
For IGF-I, the results of our meta-analysis and its graphic
plot are presented in Table 3 and Figure 1. While compar-
ing the highest to the lowest levels of IGF-I in all the stud-
ies, the people in the highest strata had a 0.87(95%CI:
0.60~1.13) times higher risk of developing lung cancer.
This association was not found to be statistically signifi-
cant. Both the Egger's test and Begg's funnel plot did not
show any publication bias (P = 0.102; Figure 2).
We also examined the possible association of IGFBP-3
and the risk of lung cancer as presented in Table 3 and Fig-
ure 3. When we compared the highest to the lowest levels
of IGFBP-3, the people in the highest strata had a
0.68(95%CI: 0.48~0.88) times higher risk of developing
breast cancer. The association was statistically significant.
Similarly, we also did not find any publication bias
between the studies (P = 0.502; Figure 4).
The individual and combined WMD of IGF-I and IGFBP-
3 are shown in Table 3. We compared circulating levels of
IGF-I and IGFBP-3 of lung cancer cases with that of con-
trols, the results are the overall WMD = -3.04(95%CI: -
7.10~1.02, P = 0.14) for IGF-I, and WMD = -
112.28(95%CI: -165.88~-58.68, P < 0.0001) for IGFBP-3.
The publication bias were also not statisitically significant
and the funnel plot were not shown.
Sensitive analysis
A single study involved in the meta-analysis was deleted
each time to reflect the influence of the individual data-set
Graphic representation of the meta-analysis for IGFBP-3 and  lung cancer Figure 3
Graphic representation of the meta-analysis for 
IGFBP-3 and lung cancer. The ORs and their 95% confi-
dence intervals in the original studies are shown..
 OR
 Study  (95% CI)  % Weight
  0.90 ( 0.28, 2.85)  Lukanova 2001   2.5 
 OR
 -5  0  1  5
 London 2002   0.50 ( 0.25, 1.02)  27.8 
 Spitz 2002   2.35 ( 1.13, 4.92)   1.1 
 Waikai 2002   0.67 ( 0.45, 1.01)  52.6 
 Ahn 2006   0.71 ( 0.35, 1.47)  13.1 
 Morris 2006   1.70 ( 0.87, 3.30)   2.8 
 Overall   0.68 ( 0.48, 0.88)  100.0 
Table 3: Individual and combined WMD, ORs and 95% CIs by IGF-I and IGFBP-3
References IGF-1 IGFBP-3
WMD(95%CI) OR(95%CI) WMD(95%CI) OR(95%CI)
[14] --- 0.54(0.14,2.07) --- 0.90(0.28,2.85)
[15] -4.00(-10.71,2.71) 0.86(0.47,1.57) -70.00(-141.14,1.14) 0.50(0.25,1.02)
[16] 5.00(-5.65,15.65) 0.64(0.3,11.33) 1300.00(-259.41,2859.41) 2.35(1.13,4.92)
[17] -2.00(-9.69,5.69) 1.74(1.08,2.81) -210.00(-332.13,-87.87) 0.67(0.45,1.01)
[18] -8.30(-17.16,0.56) 0.76(0.39,1.49) -141.00(-250.77,-31.23) 0.71(0.35,1.47)
[19] --- 1.21(0.62,2.35) --- 1.70(0.87,3.30)
Totol effect -3.04(-7.10,1.02) 0.87(0.60,1.13) -112.28(-165.88,-58.68) 0.68(0.48,0.88)
---, not available.Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89
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to the pooled ORs, and the corresponding pooled ORs
were not materially altered (data not shown).
Discussion
Lung cancer is the leading cause of malignancy-related
mortality. The mechanism of carcinogenesis is very com-
plex, which involves many factors, such as IGF-I and
IGFBP-3. Conventional studies coordinately think that
IGF-I and IGFBP-3 may promote and inhibit tumor
growth, respectively. In recent years, there are many epide-
miological studies have different results. In this meta-
analysis, our data suggests that IGF-I low in the lung can-
cer population, though we could not demonstrate statisti-
cal significance. With regard to the association between
IGFBP-3 and lung caner, the data suggests IGFBP-3 acts as
a tumor suppressor and has a inverse correlation with the
risk of lung cancer, and it does have statistical significance.
The IGF family is supposed to play a pivotal role in regu-
lating cell proliferation, apoptosis and transformation
[24]. Most circulating IGFs are produced by hepatocytes in
response to growth hormone stimulation [25-27]. Circu-
lating IGFBP-3 is produced by hepatic endothelium and
Kupffer cells [26,27]. A number of in vitro and in vivo
studies have demonstrated that IGF-I is an effective
mitogen in normal epithelial cells and has strong antiap-
optotic effects on lung cancer cells [5,10,11]. However,
the effect of IGF-I may be modulated by IGFBP-3 in circu-
lation because most of the IGF-I is bound to IGFBP-3 and
once bound it is not in its active form. The results of this
meta-analiysis indicate that there are no statistically sig-
nificant association between IGF-I and lung cancer, while
the associaton between IGFBP-3 and lung cancer is very
significant. High serum levels of IGFBP-3 associated with
a reduced lung cancer risk.
Lung cancer is a multifactorial disease that results from
complex interactions between many genetic and environ-
mental factors. This means that there will not be single
gene or single environmental factor that has large effects
on lung cancer susceptibility. Due to limited studies and
published data in original report, we could not make sub-
group analysis by sex, smoking status, histological types
and other variables. Possible limitations of our meta-anal-
ysis includes relatively small number of studies, different
heterogeneous matching factors, different countries and
ethnicities, possible publication bias, as well as possible
interaction with other biologic and environmental fac-
tors. It is well documented that ethnic factor contributes
to the lung cancer incidence. In our study, we included 2
U.S., 1 Chinese, 1 Japanese, 1 Finnish and 1 British stud-
ies. Therefore, heterogeneity by ethnicity needs to be
taken into account when interpreting our data. Heteroge-
neous matching factors and differential adjustment for
confounding factors are other sources of bias. The above
limitations might have contributed to the low statistical
power of our meta-analysis.
Despite some limitations, our results based on nested
case-control studies which represent of best study design.
In addition, we obtained the results from dichotomous
and continuous variable respectively, which made the
results more reliable. What's more, heterogeneity and
publication bias of the studies were not significant. Thus,
the data of our study are reliability.
Conclusion
In summary, we found that association between circulat-
ing levels of IGF-I, IGFBP-3 and the risk of lung cancer are
marginally and statistically significant, respectively. So it
may be helpful in the diagnosis and treatment of lung
cancer. Since circulating IGF-I and IGFBP-3 remain impor-
tant factors in lung cancer, more studies need to be con-
ducted to discern this association. And uniform
adjustment of confounding factors across the studies will
help in terms of interpretability and comparability.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
In our study, all authors are in agreement with the content
of the manuscript. Each author's contribution to the
paper: BC: First author, background literature search, data
analysis, development of final manuscript. JQW: Corre-
sponding author, research instruction, data analysis,
Funnel plot for publication bias in the analysis of IGFBP-3 and  lung cancer Figure 4
Funnel plot for publication bias in the analysis of 
IGFBP-3 and lung cancer. Each circle indicates the loga-
rithm of the odds ratio of lung cancer comparing the subjects 
in the highest category with the lowest (vertical axis) and the 
standard error of logarithm of odds ratio in each study. The 
line in the centre indicates the summary diagnostic odds 
ratio.
Begg's funnel plot with pseudo 95% confidence limits
l
o
g
[
o
r
]
s.e. of: log[or]
0 .2 .4 .6
-2
-1
0
1Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2009, 28:89 http://www.jeccr.com/content/28/1/89
Page 6 of 6
(page number not for citation purposes)
development of final manuscript. SL: background litera-
ture search, data analysis. WX: data analysis, background
literature search. XLW: research instruction, background
literature search. WHZ: research instruction, development
of final manuscript.
References
1. Spiro SG, Silvestri GA: One hundred years of lung cancer.  Am J
Respir Crit Care Med 2005, 172:523-529.
2. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P,
Hennekens CH, Pollak M: a prospective study.  Science 1998,
279:563-566.
3. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS,
Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentra-
tions of insulin-like growth factor-I and risk of breast cancer.
Lancet 1998, 351:1393-1396.
4. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH,
Stampfer MJ: Prospective study of colorectal cancer risk in
men and plasma levels of insulin-like growth factor (IGF)-I
and IGF-binding protein-3.  J Natl Cancer Inst 1999, 91:620-625.
5. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of
insulin-like growth factor-I and lung cancer risk: a case-con-
trol analysis.  J Natl Cancer Inst 1999, 91:151-156.
6. Yu H, Rohan T: Role of the insulin-like growth factor family in
cancer development and progression.  J Natl Cancer Inst 2000,
92:1472-1489.
7. Giovannucci E: Insulin, insulin-like growth factors and colon
cancer: a review of the evidence.  J Nutr.  2001, 131(11
Suppl):S3109-S3120.
8. Clemmons DR: Modifying IGF1 activity: an approach to treat
endocrine disorders, atherosclerosis and cancer.  Nat Rev Drug
Discov 2007, 6:821-833.
9. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn
A, Herbst RS, Li C, Lee HY: Antimetastatic activity of insulin-
like growth factor binding protein-3 in lung cancer is medi-
ated by insulin-like growth factor-independent urokinase-
type plasminogen activator inhibition.  Mol Cancer Ther 2006,
5:2685-2695.
10. Hofmann F, Garcia-Echeverria C: Blocking the insulin-like
growth factor-I receptor as a strategy for targeting cancer.
Drug Discov Today 2005, 10:1041-1047.
11. Tao Y, Pinzi V, Bourhis J, Deutsch E: Mechanisms of disease: sig-
naling of the insulin-like growth factor 1 receptor pathway–
therapeutic perspectives in cancer.  Nat Clin Pract Oncol 2007,
4:591-602.
12. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY: Cor-
relation between insulin-like growth factor-binding protein-
3 promoter methylation and prognosis of patients with stage
I non-small cell lung cancer.  Clin Cancer Res 2002, 8:3669-3675.
13. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK,
Lee HY: Clinical significance of insulin-like growth factor-
binding protein-3 expression in stage I non-small cell lung
cancer.  Clin Cancer Res 2002, 8:3796-3802.
14. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore
RE, Riboli E, Rinaldi S, Kaaks R: A prospective study of insulin-like
growth factor-I, IGF-binding proteins-1, -2 and -3 and lung
cancer risk in women.  Int J Cancer 2001, 92:888-892.
15. London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK, Yu
MC: Insulin-like growth factor I, IGF-binding protein 3, and
lung cancer risk in a prospective study of men in China.  J Natl
Cancer Inst 2002, 94:749-754.
16. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M:
Serum insulin-like growth factor (IGF) and IGF-binding pro-
tein levels and risk of lung cancer: a case-control study
nested in the beta-Carotene and Retinol Efficacy Trial
Cohort.  Cancer Epidemiol Biomarkers Prev 2002, 11:1413-1418.
17. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K,
Watanabe Y, Kondo T, Nishino Y, Ohno Y: Serum insulin-like
growth factors, insulin-like growth factor-binding protein-3,
and risk of lung cancer death: a case-control study nested in
the Japan Collaborative Cohort (JACC) Study.  Jpn J Cancer Res
2002, 93:1279-1286.
18. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D: No
association between serum insulin-like growth factor (IGF)-
I, IGF-binding protein-3, and lung cancer risk.  Cancer Epidemiol
Biomarkers Prev 2006, 15:2010-2012.
19. Morris JK, George LM, Wu T, Wald NJ: Insulin-like growth fac-
tors and cancer: no role in screening. Evidence from the
BUPA study and meta-analysis of prospective epidemiologi-
cal studies.  Br J Cancer 2006, 95:112-117.
20. Cochran WG: The combination of estimates from different
experiments.  Biometrics 1954, 10:101-129.
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data
from retrospective studies of disease.  J Natl Cancer Inst 1959,
22:719-748.
22. DerSimonian R, Laird N: Meta-analysis in clinical trials.  Control
Clin Trials 1986, 7:177-188.
23. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-
analysis detected by a simple, graphical test.  BMJ 1997,
315:629-634.
24. Pollak MN: Endocrine effects of IGF-I on normal and trans-
formed breast epithelial cells: potential relevance to strate-
gies for breast cancer treatment and prevention.  Breast
Cancer Res Treat 1998, 47:209-217.
25. Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Möller C,
Delhanty PJ, Baxter RC, Angelin B, Ekström TJ, Tally M: Acute and
short-term effects of growth hormone on insulin-like growth
factors and their binding proteins: serum levels and hepatic
messenger ribonucleic acid responses in humans.  J Clin Endo-
crinol Metab 1999, 84:553-560.
26. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA: Cellular localization
and regulation of gene expression for components of the
insulin-like growth factor ternary binding protein complex.
Endocrinology 1994, 134:2498-2504.
27. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ: Differ-
ential cellular synthesis of insulin-like growth factor binding
protein-1 (IGFBP-1) and IGFBP-3 within human liver.  J Clin
Endocrinol Metab 1994, 79:1871-1876.